TARRYTOWN, N.Y., Aug. 3,
2017 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ:
REGN) Due to technical difficulties in accessing
www.regeneron.com, the second quarter 2017 Financial and
Operating Results webcast can be accessed at
www.investor.regeneron.com or
http://edge.media-server.com/m/p/5wmatong beginning at
8:30 AM ET on Thursday, August 3rd, 2017. To
access this call, dial (888) 771-4371 (U.S.) or (847) 585-4405
(International). A replay of the conference call and webcast will
be archived on the Company's website and will be available for 30
days.
About Regeneron Pharmaceuticals, Inc.
Regeneron
(NASDAQ: REGN) is a leading biotechnology company that invents
life-transforming medicines for people with serious diseases.
Founded and led for nearly 30 years by physician-scientists, our
unique ability to consistently translate science into medicine has
led to six FDA-approved treatments and over a dozen product
candidates, all of which were homegrown in our laboratories. Our
medicines and pipeline are designed to help patients with eye
disease, heart disease, allergic and inflammatory diseases, pain,
cancer, infectious diseases and rare diseases.
Regeneron is accelerating and improving the traditional drug
development process through its proprietary
VelociSuite® technologies, including
VelocImmune® which yields optimized fully-human
antibodies, and ambitious initiatives such as the Regeneron
Genetics Center, one of the largest genetics sequencing efforts in
the world. For additional information about the company, please
visit www.regeneron.com or follow @Regeneron on Twitter.
Contacts
Regeneron:
|
|
Media
Relations
|
Investor
Relations
|
Arleen
Goldenberg
|
Manisha
Narasimhan, Ph.D.
|
Tel: + 1 (914)
847-3456
|
Tel: +1 (914)
847-5126
|
Mobile: +1 (914)
260-8788
|
Manisha.narasimhan@regeneron.com
|
arleen.goldenberg@regeneron.com
|
|
View original
content:http://www.prnewswire.com/news-releases/accessing-the-regeneron-second-quarter-2017-financial-and-operating-results-webcast-300499071.html
SOURCE Regeneron Pharmaceuticals, Inc.